SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Infectious Diseases Consultation — John Henry Holliday

PatientJohn Henry Holliday
Date of birth2004-08-14
IdentifiersMRN HR-NI007-SYN; SSN (made up) 000-07-8153
Document date2026-02-24
AuthorLeticia Navarro, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Referral

New cavitary, smear-positive pulmonary tuberculosis in a 21-year-old dentist who drinks heavily. Please confirm the regimen and doses, advise on liver monitoring given his alcohol use, and advise on isolation, return to dental work, and the length of treatment. [S]

Urgency: Urgent, within two weeks, on the same day as his two-week primary care visit. [S]

Questions for the consultant:

History of Present Illness

Mr. Holliday, a 21-year-old dentist, is seen at the request of Dr. Beaumont two weeks after a diagnosis of cavitary pulmonary tuberculosis. He has taken all thirteen doses of isoniazid, rifampin, pyrazinamide, and ethambutol with pyridoxine by video-observed therapy. His cough and night sweats are improving and the hemoptysis has stopped. He has mild nausea after the morning doses and orange urine and tears, and no jaundice, abdominal pain, rash, numbness, or vision change. He has cut his drinking down sharply. He has no travel outside the country, no known contact with drug-resistant tuberculosis, and no immune-suppressing condition or medicine. [S]

Historical basis. These claims are historical evidence, not findings from a modern examination.

1 later historical claim is omitted because it describes events after the index age. See the teaching note.

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Isoniazid 300 mg tablet, one tablet daily300 mg once daily by video-observed therapy with the health department, seven days a week, for six monthsOral route2026-02-12 to 2026-08-13completedS
Rifampin 300 mg capsules, two capsules (600 mg) daily600 mg once daily on an empty stomach by video-observed therapy with the health department, seven days a week, for six monthsOral route2026-02-12 to 2026-08-13completedS
Pyrazinamide 500 mg tablets, three tablets (1500 mg) daily1500 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phaseOral route2026-02-12 to 2026-04-08completedS
Ethambutol 400 mg tablets, three tablets (1200 mg) daily1200 mg once daily by video-observed therapy with the health department, seven days a week, until susceptibility results returnOral route2026-02-12 to 2026-03-10stoppedS
Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily50 mg once daily with isoniazidOral route2026-02-12 to 2026-08-13completedS

Problems

ProblemClinical statusVerificationCodeProvenance
Pulmonary tuberculosis, right upper lobe cavitary, sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistanceactiveconfirmed A15.0S — Synthetic modern coding of his documented pulmonary tuberculosis at the time of diagnosis; the bacteriology is synthetic.
Alcohol use disorder, mild, with binge drinkingactiveconfirmed F10.10S — Synthetic modern coding anchored to the documented heavy drinking; the severity and the criteria met are synthetic.

Physical Exam

Vital signs recorded on 2026-02-24; see the referring visit's Vital Signs section. [S]

SystemFinding
GeneralThin; temperature 37.3 °C, heart rate 92; seen in a negative-pressure room
EyesNo icterus; visual acuity and color vision normal
RespiratoryCoarse crackles and bronchial breathing over the right upper zone
AbdomenSoft, non-tender; liver not enlarged
NeurologicalNormal sensation in the feet
SkinNo rash

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-02-24Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma41U/L7-56 U/LNormalS
2026-02-24Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma39U/L10-40 U/LNormalS
2026-02-24Bilirubin.total [Mass/volume] in Serum or Plasma0.7mg/dL0.1-1.2 mg/dLNormalS
2026-02-24Visual acuity uncorrected Right eye by ETDRS eye chart85{letters}>=80NormalS
2026-02-24Visual acuity uncorrected Left eye by ETDRS eye chart84{letters}>=80NormalS
2026-02-24Total score [AUDIT-C]4{score}S

Assessment

Data reviewed: Dr. Beaumont's diagnostic note; the chest X-ray; the three baseline smears and the nucleic acid amplification result; today's report that the baseline cultures are growing Mycobacterium tuberculosis complex, with susceptibility pending; the HIV, hepatitis B, and hepatitis C results, all negative, with no hepatitis B immunity; and today's liver tests and vision check. [S]

Plan of Treatment